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ABSTRACT
Objective: The objective of this study was to measure the rate of persistence to
antidepressants and to identify the factors influencing persistence to these medications
in patients with diabetes.
Methods: We conducted a retrospective study among patients with diabetes enrolled
in a commercial health plan between 2009 – 2012. The study population includes
patients who were at least 18 years of age and diagnosed with major depression during
this period. The patients were eligible for acute phase treatment and continuation phase
treatment if they were enrolled at least 90 days and 180 days after the Index
antidepressant Prescription Start Date (IPSD) respectively. The patients were eligible
for the study if (1) there was no history of diagnosis of major depression for at least
120 days prior to the first episode of major depression (Index Episode Start DateIESD) and (2) there was no history of an antidepressant dispensing for at least 90 days
prior to the IPSD.
Results: The mean age of the patients in both the phases was approximately 60 years.
A majority were prescribed SSRI (Selective Serotonin Reuptake Inhibitors)
antidepressants in acute (71.5%) and continuation (74.9% ) treatment phases , 81.8%
of the patients in acute phase and 72.8% in continuation phase had monotherapy, 210
patients in acute phase and 112 patients in continuation phase had no follow up visits.
Only 60.1 % and 43.5% of patients were found to be persistent to acute and
continuation treatment phases respectively.
Acute Phase Treatment: The odds of non-persistence were higher for patients in age
group 18-40 compared to patients aged 40 above (OR 0.46 P=0.0036). Across the

class of antidepressants patients utilizing trazadone or mirtazapine (OR=2.35 P=0.02)
were more likely to non-persist. Patients who had 1 to 3 (OR=0.19 P<0.0001) or more
than 3 (OR= 0.63 P<0.0001)follow up visits were found to have lower odds for non
persistence compared to patients with no follow up visits during the treatment. Patients
who had a combination treatment with either buproprion or tricyclic antidepressants
(TCA) were found to be more likely to non-persist (OR 2.85 P=0.003).
Continuation Phase Treatment: The odds of non-persistence were higher for patients in
age group 18-40 compared to patients aged 40 above (OR 0.52 P=0.03). Patients who
had 1 to 3 (OR 0.1 P<0.0001) or more than 3 (OR 0.13 P<0.0001)follow up visits
were found to have lower odds for non-persistence compared to patients with no
follow up visits during the treatment period
Conclusion: In this population of commercially-insured patients having diabetes,
acute phase persistence with antidepressant therapy was found to be associated with
age, antidepressant class, type of therapy and intensity of follow up visits where as
continuation treatment persistence was associated with age and intensity of follow up
visits.

ACKNOWLEDGMENTS
I would like to earnestly thank my major professor Dr. Larrat, whose support is
the main reason I could complete this project. I thank him for all the guidance,
resources and opportunities he has provided me since I started my masters program. I
thank him for the knowledge I have gained, for his prompt responses and feed backs
given to me whenever needed. His kindness and disposition will always be an
inspiration to me.
I would also like to heartfully thank Dr. Kogut for his immense support during this
project. I am always grateful for his guidance which enabled me to think better and
work efficiently on my project. Working with him not only enhanced my research and
technical skills but also my personal qualities such as being positive, dedication to
work and being optimistic. I also thank him for providing the data for this project and
allowing me to work on other research projects.
I would also like to thank Dr. Willey, whose classes equipped me with basic and
fundamental research skills. The two courses she taught were the best classes I have
taken here. I also thank her for time and feedback on my class work which I was able
to apply to my thesis work.
I would also like to sincerely thank Dr. Rosenbaum and Professor Marcoux for being
on my committee and providing suggestions to further improve my work.
I am also very thankful to my parents and my sister who have been a source of infinite
love and encouragement to me. It would not have been possible for me to complete
this project without their support.
Once again I would like to express my deepest gratitude to Dr. Larrat and Dr. Kogut.

iv

TABLE OF CONTENTS

ABSTRACT………………………………………………………………………….ii
ACKNOWLEDGMENTS…………………………………………………………..iv
TABLE OF CONTENTS……………………………………………………………v
LIST OF TABLES…………………………………………………………………...vi
LIST OF FIGURES…………………………………………………………………vii
CHAPTER 1…………………………………………………………………………1
INTRODUCTION………………………………………………………………1
CHAPTER 2…………………………………………………………………………4
METHODOLOGY………………………………………………………………4
CHAPTER 3…………………………………………………………………………11
FINDINGS………………………………………………………………………11
CHAPTER 4…………………………………………………………………………21
DISCUSSIONS, LIMITATIONS AND CONCLUSIONS…………………… 21
APPENDICES………………………………………………………………………25
BIBILOGRAPHY…………………………………………………………………..32

v

LIST OF TABLES

TABLE

PAGE

Table 1. Demographic and clinical characteristics of a population of commercially
insured patients with diabetes: Acute Phase persistence with antidepressant
medication… ............................................................................................................... 14
Table 2. Bivariate Analysis: Factors associated with persistence to acute phase
antidepressant treatment in commercially insured patients with diabetes .................. 15
Table 3. Estimated odds ratios and 95% confidence intervals of antidepressant
treatment persistence during acute phase treatment .................................................... 16
Table 4. Demographic and clinical characteristics of a population of commercially
insured patients with diabetes: Continuation Phase persistence with antidepressant
medication ................................................................................................................... 17
Table 5. Bivariate Analysis: Factors associated with persistence continuation phase
antidepressant treatment in commercially insured patients with diabetes ................. 18
Table 6. Estimated odds ratios and 95% confidence intervals of antidepressant
treatment persistence during continuation phase treatment ........................................ 19

vi

LIST OF FIGURES

FIGURE

PAGE

Figure 1. Time frame for the enrollment of subjects in the study. ................................ 6
Figure 2. Eligible population for acute phase treatment persistence measurement. ..... 7
Figure 3. Eligible population for continuation phase treatment persistence
measurement ................................................................................................................. 8

vii

CHAPTER 1

INTRODUCTION

In the United States the prevalence of diabetes is increasing with approximately 8%
of the population or 26 million people diagnosed with this disease.1 It is very crucial
for patients with diabetes to adhere to their medication to have glycemic control 2and
also to decrease hospitalizations and health care costs.3
Approximately 15 million adults in the United States are affected by major
depression which is highly recurrent.4,5 It is estimated that 9.5% of the adult
population suffer from depressive illness every year.6 People with depression have
negative effects such as suicidal behavior, higher health care utilization and costs,
lower quality of life and reduction in employment productivity.7-9 To achieve previous
levels of functioning and to prevent reoccurrence of depression, adherence to
antidepressant medication is critical.10-12
The increased prevalence of depressive symptoms and major depressive disorder in
patients with diabetes has been documented by many studies.13 The prevalence of
depression in diabetic population is approximately double the prevalence of
depression in the general population.14

Symptoms of depression are present in

approximately 30% of people with diabetes

15

and approximately 10% of people with

diabetes have major depression.16 Li et al found that 45% of patients with diabetes
have undiagnosed depression which suggests even higher rates of prevalence of both
these conditions together.17 Comorbid depression in diabetes patients is severe and

1

persistent.18 Lustman et al found that in patients with comorbid major depression and
diabetes the rates of relapse of depression were as high as 79% over 5 year period with
a mean of 4 or more episodes during that period.19,20
Patients with comorbid diabetes and depression are more likely to be non-adherent to
the medication regimen21 and also show poor diabetes management compared to
patients without depression.22 Depression is associated with higher hemoglobin A1c
(HbA1c) levels,23 poor adherence to diet, exercise and medication regimen in patients
with diabetes.24-27 It is also associated with greater symptom burden,28 functional
impairment,25,26 micro and macro vascular complications,29 higher health care costs26
and mortality.29 For example a study conducted by Ciechanowski et al on patients
enrolled in a health maintenance organization having diabetes with higher severity of
depression symptoms, subjects had worse physical and mental functioning, higher
non-adherence to oral hypoglycemic regimens (15% vs. 7%) 51% higher primary ,
75% higher ambulatory and 86% higher total health care costs compared to patients
with low severe symptoms of depression.26 These facts suggest the importance of
effective treatment of depression in patients with diabetes to improve the health
outcomes.
When compared to non-depressed patients, depressed patients are three times more
likely to be non-adherent to treatment recommendations.

30

In one study conducted

amongst primary care patients about one-third discontinued their antidepressant
therapy within one month of the initiation of the treatment and about half discontinued
within three months.31 Lowest rates of adherence were found in patients with diabetes
(67.5%) compared to patients with other chronic conditions (pulmonary-68.8% and

2

cardiovascular diseases-76.6%) in a study conducted by DaMatteo et al.32 These facts
together suggest even lower adherence rates in patients with comorbid depression and
diabetes. A major barrier to improving care in people with comorbid depression and
diabetes is their poor adherence to the treatment.30
The objective of this study was to measure the rate of persistence to antidepressants
and to identify the factors influencing persistence to these medications in patients with
diabetes.
We hypothesized that one of the covariates among the patient demographic (age,
gender, health plan) or clinical factors (Comorbidity score, insulin utilization,
hospitalization, psychotherapy, type of antidepressant, class of antidepressant, type of
therapy) or physician factors (follow up visits) better predicts the persistence to
antidepressant therapy.
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CHAPTER 2

METHODOLOGY

Study Design: We conducted a retrospective cohort study using a sample of
commercially insured patients. The data set consisted of health care claims occurring
from 2009 through 2012. All the members of this dataset have at least one
International Classification of Disease-9 (ICD-9) code for diabetes during this period.
The enrollment file has demographic information describing age, gender, health plan,
enrolment start date and end date. The prescription file contains information
describing National Drug Codes (NDC), drug names, dates of prescription dispensing ,
days of supply of the medication provided, national provider ID, copayment and
prescription cost. The professional file includes information describing medical
service use including diagnosis and procedure codes and payment amounts. The
facility file has information describing ICD codes, Current Procedural Terminology
(CPT) codes, revenue codes, copayment, cost paid to the facility, admit dates and
discharge dates.
Study population: The study population includes patients enrolled in the
commercial plan who were at least 18 years of age and diagnosed with major
depression during 2009-2012 (International Classification of Diseases codes 296.20296.25, 296.30-296.35, 298.0, 311). The patients were eligible for acute phase
treatment and continuation phase treatment if they were enrolled at least 90 days and
180 days after the Index antidepressant Prescription Start Date (IPSD) respectively.
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The patients were eligible for the study if (1) there was no history of diagnosis of
major depression for at least 120 days prior to the first episode of major depression
(Index Episode Start Date-IESD) and (2) there was no history of an antidepressant
dispensing for at least 90 days prior to the IPSD. Since persistence with particular
drug therapy was a variable of our interest, we excluded the patients who switched the
drug therapy during the treatment period.

5

Figure 1. Time frame for the enrollment of subjects in the study

Index Prescription Start Date
Date

Negative Medication History

90 Days

Continuous Phase Treatment

84Days

Acute Phase Treatment

96 Days

6

Figure 2. Eligible population for acute phase treatment persistence measurement

Patients with diagnosis for Major Depression (N=2587)

Therefore N= 2663-76=2587

Patients with Negative Diagnosis History
(NDH) N=2247 (86.8%)

Patients with Negative Medication history
(NMH) and at least 90 day follow up after IPSD
N=756 (29.2%)

Patients with both NDH and NMH N=717 (27.7%)

Patients with age less than 17(N=7) and
Switching (N=23)

Final Sample N=687(26.5%)
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Figure. 3 Eligible population for continuation treatment phase persistence
measurement

Patients with diagnosis for Major Depression (N=2587)

Therefore N= 2663-76=2587

Patients with Negative Diagnosis History
(NDH) N=2247 (86.8%)

Patients with Negative Medication history
(NMH) and at least 180 day follow up after
IPSD N=738 (28.4%)

Patients with both NDH and NMH N=650 (25.13%)

Patients with age less than 17(N=7) and
Switching (N=41)

Final Sample N=602(23.27%)
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Dependent Variable: The dependent variable for the study was persistence to the
antidepressant therapy. Effective acute phase treatment was defined as at least 84 days
of continuous treatment with antidepressants within 114 days after the IPSD. Effective
continuous phase treatment was defined as at least 180 days of continuous treatment
with antidepressants within 231 days after the IPSD. The patients who meet these
criteria were identified as persistent to therapy and who do not meet were identified as
non-persistent to the therapy. The persistence to therapy during acute phase and
continuous phase were evaluated in different models.
Independent variables: Age, gender, Charlson comorbidity index, insulin utilization,
hospitalization, psychotherapy, class and type of the antidepressant, type of
antidepressant therapy, health plan and intensity of follow- up care were the
independent variables examined in this study. Age was coded in categories with age
group 18-40 and above 41. The classes of antidepressants considered were tricyclic
antidepressants (TCA), SSRI’s (Selective Serotonin Reuptake Inhibitors), SSNRI’s
(Selective Serotonin Norepinephrine Reuptake Inhibitors), phenyl piperazines,
tetracyclic antidepressants and bupropion. The Charlson comorbidity index provides
the overall measure of disease burden and predicts the mortality by weighing different
comorbid conditions of the patient; this score was calculated for each patient for all
the disease conditions in the time frame studied and was used for assessing the
comorbidity of the patients in this study. The score was coded in categories with
scores of 1 to 3 and more than 3. Follow up visits for any purpose during the treatment
phase were counted for both the phases. The visits were coded as 0, 1-3 visits and
more than 3 visits.

9

Statistical Analysis: Descriptive statistics for each variable were used to summarize
the study population. Bivariate analyses were conducted to assess the association
between the dependent variable and each independent variable. Univariate logistic
regression was performed to select the variables with significant P-Values (0.2) for
final model (Table 7 and Table 8 in Appendix). Interactions and colinearity were
assessed between the independent variables. Multivariate logistic regression was
performed to examine the multivariate associations of the independent variables with
the dependent variable (persistence to antidepressant therapy during acute phase
treatment and continuous phase treatment) and odds ratios were used to measure the
association. Separate analyses were performed for the acute and continuous phases.
The significance level was set at 0.05 and 95% Confidence Intervals were examined.
All the statistical analyses were performed using SAS statistical software version 9.3.

10

CHAPTER 3

FINDINGS

Acute Phase Treatment Persistence
Table 1 provides the base line demographic and clinical characteristics of the study
population. The mean age of this population was 60.5 years and a majority of the
patients were females (56.8%).The mean comorbid score in this study population was
3.4. Additionally 44.69% of the patients received psychotherapy during the acute
phase treatment. Insulin utilization was observed in 31% of these patients. Forty- four
(6.4%) patients were hospitalized. A majority (65.2%) of them were enrolled in nonHMO (Health Maintenance Organization) plans. Most of these patients (81.8%) had
antidepressant monotherapy. No follow up visits were in 30.6% of patients during the
treatment period. Generic antidepressant drugs were prescribed to 84.6% of the
patients. A majority of the population (71.5%) were prescribed SSRI’s followed by
SSNRI’s (8.7%).

In the bivariate analysis (Table 2) age, antidepressant class, type of therapy and follow
up visits were found to have a significant association with persistence to
antidepressant medication during the acute phase treatment. Patients adherent during
the acute phase were aged 41 or above (61.8%) vs. 18-40 years (47.5%), prescribed an
SSRI antidepressant (61.7%) or SSNRI (63.3%) or bupropion (64.1%) and were on
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monotherapy (62.6%). Higher rates of persistence were found in patients having 1-3
(79.4%) or more than 3 follow up visits (53.9%).

In the multivariate analysis (Table 3) age, class of antidepressant, type of therapy and
follow up visits were found to be significantly associated with persistence to acute
phase treatment after adjusting for other variables. The odds of non-persistence were
higher for patients in age group 18-40 compared to patients aged 40 above (OR 0.46
P=0.0036). Across the class of antidepressants patients utilizing other (trazadone and
mirtazapine) antidepressants (OR=2.35 P=0.02) were more likely to not persist
compared to patients utilizing SSRI’s, whereas no difference was observed in the rates
of persistence in patients utilizing SSNRI’s, TCA, bupropion and SSRI’s. Patients
who had 1 to 3 (OR=0.19 P<0.0001) or more than 3 (OR= 0.63 P<0.0001)follow up
visits were found to have lower odds for non-persistence compared to patients with no
follow up visits during the treatment. Patients who had a combination treatment with
either buproprion or TCA were found to be more likely to non-persist (OR 2.85
P=0.003) where as there was no difference in rates of persistence in patients who had a
combination treatment either with trazadone or mirtazapine.
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Continuation Phase Treatment Persistence
Table 4 shows the baseline demographic and clinical characteristics of the population
in the continuous phase. The mean age of the study population during this treatment
was 60.4. The proportion of females was higher (56.8%) than males. The mean
comorbid score for this population was 3.4. Approximately 43% of patients received
psychotherapy during this period. Insulin utilization was observed in 30.7% of the
patients. Fourty patients (6.6%) were hospitalized during this period. Similar to the
population in acute phase treatment a majority of the patients (65.8%) in this treatment
phase were also enrolled in a non-HMO health plan. A higher percentage of people
had monotherapy (72.8%). No follow up visits were observed in 18.6% of patients
during the treatment period. Most of the patients were prescribed (83.6%) generic
antidepressants similar to the patients in acute phase treatment. A majority of them
were prescribed SSRI’s (74.9%) followed by SSNRI’s (9.0%).

In the bivariate analysis (Table 5) age and follow up visits were found to have a
significant association with persistence to antidepressant medication during the
continuous phase treatment. Patients adherent during the continuous phase were aged
41 or above (45.1%) vs. 18-40 years (30.3%). Higher rates of persistence were found
in patients having 1-3 (56.2%) or more than 3 (48.9%) follow up visits compared to
patients with no follow up visits (11.6%).
In the multivariate analysis (Table 6) age and follow up visits were found to be
significantly associated with persistence to continuous phase treatment after adjusting
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for other variables. The odds of non-persistence were higher for patients in age group
18-40 compared to patients aged 40 above (OR=0.52 P=0.03). Patients who had 1 to 3
(OR=0.1 P<0.0001) or more than 3 (OR=0.13 P<0.0001)follow up visits were found
to have lower odds for non-persistence compared to patients with no follow up visits
during the treatment period.
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Table 1. Demographic and clinical characteristics of a population of commercially
insured patients: Acute phase persistence with antidepressant medications (N=687)
Variable
Age(Mean 60.5,SD16.7)
18-40
41-64
65 and above
Gender
Male
Female
Comorbidity Score(Mean 3.4,SD 2.7)
1
2
3 or more
Insulin
Yes
No
Hospitalization
Yes
No
Psychotherapy
Yes
No
Type of Antidepressant
Generic
Brand
Brand and Generic
Antidepressant Class
SSRI
SSNRI
Tricyclic Antidepressants
Bupropion
Others
Type of therapy
Monotherapy
Combination with
trazadone/mirtazapine
Combination with Others
Health Plan
HMO
Non-HMO
Follow up Visits
0
1 to 3
more than 3

15

N

%

80
352
255

11.7
51.3
37.0

297
390

43.2
56.8

214
106
367

31.0
15.5
53.5

213
474

31
69

44
643

6.4
93.6

307
380

44.7
55.3

581
81
25

84.6
11.8
3.6

491
60
39
39
58

71.5
8.7
5.7
5.7
8.4

562

81.8

85
40

12.4
5.8

239
448

34.8
65.2

210
247
230

30.6
35.9
33.5

Table2. Bivariate Analysis: Factors associated with persistence to acute phase
antidepressant treatment in commercially insured patients
Variable

Persistent

Non-Persistent

413(60.1%)

274(39.9%)

Chi-Sq P-value

0.014

Age
18-40

38 (47.5%)

42(52.5%)

41 and above

375(61.8%)

232(38.2%)
0.07

Gender
Male
Female

190(64%)
223(57.2%)

107(36%)
167(42.8%)

Comorbidity Score
1 to 3

266(60.9%)

171(39.1%)

4 and above

147(58.8%)

103(41.2%)

Insulin
Yes
No

123(57.7%)
290(61.2%)

90(42.3%)
184(38.8%)

Hospitalization
Yes

29(65.9%)

15(34.1%)

No

384(59.7%)

259(40.3%)

Psychotherapy
Yes
No

194(63.2%)
219(57.6%)

113(36.8%)
161(42.4%)

Type of Antidepressant
Generic

351(60.4%)

230(39.6%)

Brand
Generic and Brand

47(58%)
15(60%)

34(42%)
10(40%)

Antidepressant Class
SSRI

306(61.7%)

185(37.7%)

SSNRI
Tricyclic Antidepressants

38(63.3%)
17(43.6%)

22(36.7%)
22(56.4%)

Bupropion
Others

25(64.1%)
27(46.6%)

14(35.9%)
31(53.4%)

Type Of Therapy
Monotherapy

352(62.6%)

210(37.4%)

Combination with Trazadone/ Mirtazapine
Combination with Others

44(51.8%)
17(42.5%)

41(48.2%)
23(57.5%)

0.59

0.4

0.42

0.14

0.91

0.03

0.01

0.55

Health Plan
HMO

140(58.6%)

99(41.4%)

Non-HMO

273(60.9%)

175(39.1%)
<0.0001

Follow up Visits
0
1 to 3

93(44.3%)
196(79.4%)

117(55.7%)
51(20.6%)

More than 3

124(53.9%)

106(46.1%)
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Table 3. Estimated odds ratios and 95% confidence intervals of antidepressant
treatment persistence during acute phase treatment
Variable

Odds Ratio

95% CI

P-Value
0.0036

Age
18-40

1

41 and above

0.46

0.27-0.78
0.069

Gender
Male

0.73

Female

1

0.52-1.03

0.6

Comorbidity Score
1 to 3

1

4 and above

1.09

0.76-1.56
0.02

Antidepressant Class
SSRI

1

SSNRI

0.94

0.52-1.71

TCA

1.62

0.78-3.31

Bupropion

0.83

0.4-1.7

Others

2.35

1.29-4.29
<0.0001

Follow up visits
0

1

1 to 3

0.19

0.12-0.29

more than 3

0.63

0.42-0.93
0.003

Type of therapy
Monotherapy
Combination with Trazadone/
Mirtazapine

1
1.74

1.05-2.88

Combination with Others

2.85

1.41-5.78
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Table 4. Demographic and clinical characteristics of a population of commercially
insured patients: Continuation phase treatment persistence with antidepressant
medications
Variable
Age(Mean60.4,SD16.2)
18-40
41-64
65 and above
Gender
Male
Female
Comorbidity Score(Mean3.4,SD2.6)
1
2
3 or more
Insulin
Yes
No
Hospitalization
Yes
No

N

%

66
319
217

11.0
52.9
36.1

260
342

43.2
56.8

186
94
322

30.9
15.6
53.5

185
417

30.7
69.3

40
562

6.6
93.4

Psychotherapy
Yes
No

257
345

42.7
57.3

Type of Antidepressant
Generic
Brand
Brand and Generic

503
59
40

83.6
9.8
6.6

451
54
35
29
33

74.9
9.0
5.8
4.8
5.5

438
109
55

72.8
18.1
9.1

206
396

34.2
65.8

112
128
362

18.6
21.3
60.1

Class of Antidepressant
SSRI
SSNRI
Tricyclic Antidepressants
Bupropion
Others
Type of therapy
Monotherapy
Combination with Trazadone/Mirtazapine
Combination with other
Health Plan
HMO
Non-HMO
Follow up Visits
0
1 to 3
more than 3
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Table 5. Bivariate Analysis: Factors associated with persistence to continuation phase
antidepressant treatment in commercially insured patients
Variable

Persistent
262(43.5%)

Non-Persistent
340(56.5%)

Age
18-40
41 and above

20(30.3%)
242(45.1%)

46(69.7%)
294(54.9%)

Gender
Male
Female

115(44.2%)
147(43%)

145(55.8%)
195(57%)

Comorbidity Score
0 to 3
4 and above

163(42.7%)
99(45%)

219(57.3%)
121(55%)

Insulin
Yes
No

79(42.7%)
183(43.9%)

106(57.3%)
234(56.1%)

Hospitalization
Yes
No

13(32.5%)
249(44.3%)

27(67.5%)
313(55.7%)

Psychotherapy
Yes
No

0.02

0.8

0.6

0.8

0.1

0.3
118(45.9%)
144(41.7%)

139(54.1%)
201(58.3%)
0.6

Type Of Antidepressant
Generic
Brand
Generic and Brand

218(43.3%)
24(40.7%)
20(50%)

285(56.7%)
35(59.3%)
20(50%)

Antidepressant Class
SSRI
SSNRI
Tricyclic Antidepressants
Bupropion
Others

199(44.1%)
28(51.9%)
11(31.4%)
13(44.8%)
11(33.3%)

252(55.9%)
26(48.1%)
24(68.6%)
16(55.2%)
22(66.7%)

201(45.9%)

237(54.1%)

38(34.7%)
23(41.8%)

71(65.1%)
32(58.2%)

Type of Therapy
Monotherapy
Combination with
Trazadone/Mirtazapine
Combination with Other
Health Plan
HMO
Non-HMO
Follow up visits
0
1 to 3
More than 3

Chi-Sq P-value

0.3

0.1

0.7
92(35.1%)
114(33.5%)

170(64.9%)
226(66.5%)
<0.0001

13(11.6%)
72(56.2%)
177(48.9%)
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99(88.4%)
56(43.8%)
185(51.1%)

Table 6. Estimated odds ratios and 95% confidence intervals of antidepressant
treatment persistence during continuation phase treatment
Variable

Odds Ratio

95% CI

P-Value
0.03

Age
18-40

1

41 and above

0.52

0.29-0.94
0.86

Gender
Male

0.99

Female

1

0.70-1.41

0.99

Comorbidity Score
0-3

1

4 and above

0.97

0.67-1.38
<0.0001

Follow Up Visits
0

1

1 to 3

0.1

0.05-0.19

more than 3

0.13

0.07-0.25
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CHAPTER 4

DISCUSSIONS, LIMITATIONS AND CONCLUSION

In this study we assessed the antidepressant treatment persistence rates and the
factors associated with persistence to these medications in the acute phase and
continuation phase treatment periods. Results of our study indicate that only 60.12 %
and 43.52 % of patients were persistent to acute and continuation phase respectively.
Persistence was significantly influenced by age, class of antidepressant, type of
therapy and intensity of follow up visits during the acute phase treatment where as
only age and intensity of follow up visits had an effect on persistence to the therapy
during continuation phase.

As expected a majority of the patients were prescribed SSRI’s as they are most
frequently utilized for depression and the preferable antidepressants for diabetic
patients as they might show beneficial effects on glycemic control.33-35

Older age was found to be associated with persistence to the antidepressant medication
in both acute and continuous phases. This finding was consistent with the previous
research36-38 that older people were more likely to be adherent to the therapy compared
to younger people. For example, in a study conducted by Akincigil et al on privately
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insured patients, patients who were age 50 or above were found to be 2.48 times more
likely to be adherent compared to patients with 18-25 years. This might be due to the
possibility that older people are more experienced in managing their medication
regimen to various disease conditions which makes it easier for them to manage
antidepressant medication as well. Another possible explanation might be they are
more worried about mortality compared to younger population.

The class of antidepressant utilized was significantly associated with persistence
during the acute phase but had no influence during the continuation phase. This might
be due to the side effects or adverse events due to these drugs during the initial
treatment. It could be assumed that patients who had no side effects with these drugs
in acute phase treatment persisted with their medication in continuation phase and
therefore the class of drug had no influence on persistence in this phase .Patients who
were prescribed SSRI’s were more likely to be persistent to acute phase treatment
which was a similar result in previous studies39. There was no difference in the rates of
persistence to the therapy among SSRI’s SSNRI’s, TCA and bupropion. Patients
receiving other antidepressants (trazadone and mirtazapine) were less likely to persist
with effective acute phase treatment. One reason for this might be that these drugs
were prescribed for insomnia while the primary treatment was psychotherapy. Another
reason might be due to the adverse effects of these drugs such as weight gain,
dizziness etc.
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It was also found that patients who had a combination therapy with SSRI/SSNRI and
bupropion or TCA were less likely to persist. This might be due to the side effects due
to the combination of these drugs such as remarkably lower blood pressure with
combination of TCA and SSRI.40 However a meta-analysis by Seetal et al found that
combination of SSRI/SSNRI with bupropion was well tolerated.41 Another reason
might be these patients have severe depression resulting in less motivation to take the
medicines.

We also found that patients who have either 1 to 3 or more than 3 follow up visits are
more likely to be persistent to the therapy compared to patients with no follow up
visits. It was found in the previous research that patients with 3 or more follow up
visits were more likely to persist.36,37,42 One reason for this might be that the physician
could possibly educate the patient about the importance of taking the medications
regularly. Another reason might be these patients are more cautious about their health
and therefore have frequent follow up visits with the physician and take their
medications regularly.

Our study has several limitations. (1)Reliance on claims data, which might have
coding errors due to insufficient information provided by the physician about ICD
codes, CPT codes etc. Also the deliberate miscoding of major depression with other
diagnosis codes by physicians43 further increases the chances of coding errors in
identifying patients with major depression. (2)If the patient receives prescription or
care outside the health plan network or if the patient receives samples by the provider
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in the office it will not be shown in the claims data. (3)We assumed that patients who
had prescription for the antidepressants as persistent which might not actually reflect
the actual utilization of these drugs by the patients.(4) In the HEDIS (Healthcare
Effectiveness Data and Information Set) algorithm patients who switched the
therapies are also included in the calculation of rates of persistence but in this study
since we excluded them so the rates of persistence in this study might be
underestimated if the patients who switched their therapy were persistent.(5)The
generalization of these results might be limited to commercial health plans and
patients with diabetes.

In this population of commercially insured patients having diabetes, acute phase
persistence with antidepressant therapy was found to be associated with age,
antidepressant class, type of therapy and intensity of follow up visits where as
continuation treatment persistence was associated with age and intensity of follow up
visits.
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APPENDICES
Table 7. Results of univariate logistic regression analysis for acute phase treatment
persistence
Variable

Persistent

Non Persistent

Odds Ratio

Age
18-40

38(5.53%)

42(6.11%)

1

41 and above

375(54.59%)

232(33.77%)

0.56

Gender
Female

223(32.46%)

167(24.31%)

1

Male

190(27.66%)

107(15.57%)

0.75

Comorbidity Score
3-Jan

266(38.72%)

171(24.89%)

1

4 or more

147(21.4%)

103(14.99%)

1.09

95% CI

P-Value
0.015

(0.35-0.89)
0.07
0.55-1.03
0.59
(0.8-1.5)
0.39

Insulin
Yes

123(17.9%)

90(13.1%)

1.15

No

290(42.2%)

184(26.78%)

1

Hospitalization
Yes

29(4.22%)

15(2.18%)

0.77

No

384(55.9%)

259(4.22%)

1

Psychotherapy
Yes

194(28.24%)

113(16.45%)

0.79

No

219(31.88%)

161(23.44%)

1

0.83-1.6
0.4
0.4-1.46
0.14
0.58-1.08
0.9

Tpe of Antidepressant
Generic

351(51.09%)

230(33.48%)

1

Brand

47(6.84%)

34(4.95%)

1.1

0.69-1.77

Generic and Brand

15(2.18%)

10(1.46%)

1.02

0.45-2.4

Antidepressant Class
SSRI

306(44.54%)

185(26.93%)

1

SNRI

38(5.53%)

22(3.2%)

0.96

0.55-1.67

TCA

17(2.47%)

22(3.2%)

2.14

1.1-4.14

Bupropion

25(3.64%)

14(2.04%)

0.93

0.47-1.83

Others

27(3.93%)

31(4.51%)

1.9

1.01-3.3

0.04

0.012

Type of Therapy
Monotherapy
Combination with Trazadone
or Mirtazapine

352(51.24%)

210(30.57%)

1

44(6.40%)

41(5.97%)

1.56

0.9-2.5

Combination with Other

17(2.47%)

23(3.35%)

2.27

1.18-4.34

Health Plan
HMO

140(20.38%)

99(14.41%)

1

Non-HMO

273(39.74%)

175(25.47%)

0.9

0.66-1.25
<0.001

Follow up Visits
0

93(13.54%)

117(17.03%)

1

1 to 3

196(28.53%)

51(7.42%)

0.21

0.14-0.31

more than 3

124(18.05%)

106(15.43%)

0.68

0.47-0.99
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Table 8. Result of univariate logistic regression analysis for continuation phase
treatment persistence.
Variable
Age
18-40
41 and above
Gender
Female
Male
Comorbidity Score
0-3
4 or more
Insulin
Yes
No
Hospitalization
Yes
No
Psychotherapy
Yes
No
Type of Antidepressant
Generic
Brand
Generic and Brand
Antidepressant Class
SSRI
SSNRI
TCA
Bupropion
Others
Type of Therapy
Monotherapy
Combination with
Trazadone/Mirtazapine
Combination with other
Health Plan
HMO
Non-HMO
Follow Up Visits
0
1 to 3
more than 3

Persistent

Non-Persistent

Odds
Ratio

95% CI

20(3.32%)
242(40.20%)

46(7.64%)
294(48.84%)

1
0.53

0.3-0.9

P-Value
0.02

0.76
147(24.42%)
115(19.10%)

195(32.39%)
145(24.09%)

1
0.95

163(27.08%)
99(16.45%)

219(36.38%)
121(20.10%)

1
0.91

79(13.12%)
183(30.4%)

106(17.61%)
234(38.87%)

1.05
1

0.74-1.49

13(2.16%)
249(41.36%)

27(4.49%)
313(51.99%)

1.65
1

0.84-3.27

118(19.6%)
144(23.92%)

139(23.09%)
201(33.39%)

0.84
1

0.6-1.17

0.69-1.32
0.58
0.65-1.27
0.78

0.15

0.3

0.6
218(36.21%)
24(3.99%)
20(3.32%)

285(47.34%)
35(5.81%)
20(3.32%)

1
1.12
0.77

199(33.06%)
28(4.65%)
11(1.83%)
13(2.16%)
11(1.83%)

252(41.86%)
26(4.32%)
24(3.99%)
16(2.66%)
22(3.65%)

1
0.73
1.72
0.97
1.58

201(33.39%)

237(39.37%)

1

38(6.13%)
23(3.82%)

71(11.79%)
32(5.32%)

1.59
1.18

92(15.28%)
170(28.24%)

114(18.94%)
226(37.54%)

1
1.07

13(2.16%)
72(11.96%)
177(29.40%)

99(16.45%)
56(9.3%)
185(30.73%)

1
0.1
0.14

0.65-1.93
0.4-1.46
0.29
0.42-1.29
0.82-3.6
0.46-2.07
0.75-3.33
0.1

1.02-2.45
0.67-2.08
0.68
0.76-1.5
<0.0001
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0.05-0.2
0.07-0.3

Model Building
Acute Phase Treatment Persistence:
Univariate logistic regression was performed between the dependent variable and each
independent variable and interactions were assessed between the significant variables.
Age, gender, psychotherapy, antidepressant class, type of therapy and follow up visits
were found to be significant at a P-value significance of 0.2 for the acute phase
treatment (Table 7).Psychotherapy and gender became non significant in the
multivariate analysis. The model with interaction and the model with no interactions
were compared to select the final model.
Model 1: No-interaction model
Model 2: Model with interactions
The AIC (Akaike Information Criterion) of model 1 and model 2 were 847.6 and
847.5 respectively. The models were
compared using log likelihood ratio test.
Likelihood Ratio Test.
H0: Model 1
Ha: Model 2
LR Test:
2 Log L model1 – 2 Log L model 2 = 827.5-823.64=3.9
Degrees of Freedom = 12-10=2

P-Value= 0.14

The LR test suggests that the model with no interactions terms included explains
better. Also the co linearity diagnostics indicate co linearity in the model with
interactions as the variance inflation factors for all the variables (except age) were
greater than 6. Thus the model with no interactions was selected as the final model.
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The variance inflation factors in the model with no interaction terms were close to 1
and the condition index was less than 30 confirming no colinearity. The model fit was
assessed using Hosmer-Lemeshow Goodness of fit (GOF) and ROC curves. The GOF
P-value (0.9) was greater than 0.05 and AUC (0.7) was greater than 0.5indicating an
adequate model fit
Table 9. Goodness of Fit test for acute phase model
Hosmer- Lemeshow Goodness-of-Fit Test

Chi-Square

DF

Pr > ChiSq

2.9328

8

0.9385

Figure 4. Receiver Operating Characteristic (ROC) Curve for acute phase model
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Continuation Treatment Phase Persistence
Age, follow up visits, hospitalization and type of therapy were found to be significant
in the univaraite logistic regression for continuation phase treatment. No interactions
between these variables were found to be significant. When all variables that were
significant in the univariate logistic regression were included in the model
hospitalization and type of therapy were non-significant. Therefore, the final model
included the clinically important variables such as gender and comorbity score along
with significant variables age and follow up visits. This model was then assesses for
co linearity. The variance inflation factors were near to 1 and the condition index was
less than 30 confirming no co linearity in this model. The model fit was assessed using
Hosmer-Lemeshow Goodness of Fit and ROC curves. The GOF P-value (0.6) was
greater than 0.05 and AUC (0.65) was greater than 0.5indicating an adequate model fit

Table 10. Goodness of Fit for continuation phase model
Hosmer and Lemeshow Goodness-of-Fit
Test
Chi-Square

DF

Pr > ChiSq

4.7911

7

0.6854
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Figure 5. ROC Curve for continuation phase model

DV and IV Coding
Dependent Variable
Persistence to antidepressant medication: Yes (1) No (0)
Independent Variables
1. Age : 18-40 (1) 40 Above (2)
2. Gender : Female (1) Male (2)
3. Comorbdity Score
0-3 (1)
3 or more (2)
4. Psychotherapy : Yes (1) No (0)
30

5. Insulin : Yes (1) No (0)
6. Antidepressant Class
SSRI (1)
SSNRI (2)
TCA (3)
Bupropion (4)
Trazadone and Mirtazapine (5)
7. Type of Antidepressant
Generic (1)
Brand (2)
Brand and Generic (3)
8. Type of Antidepressant therapy
Monotherapy (0)
Combination (1)
9. Hospitalization: Yes (1) No (0)
10. Health Plan: HMO (1) Non-HMO (2)
11. Follow up visits
0 (1)
1 to 3 (2)
More than 3 (3)
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